PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TXG vs. META
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between TXG and META is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

TXG vs. META - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and Meta Platforms, Inc. (META). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-48.06%
30.86%
TXG
META

Key characteristics

Sharpe Ratio

TXG:

-1.14

META:

1.56

Sortino Ratio

TXG:

-2.27

META:

2.06

Omega Ratio

TXG:

0.72

META:

1.28

Calmar Ratio

TXG:

-0.81

META:

2.57

Martin Ratio

TXG:

-1.36

META:

7.78

Ulcer Index

TXG:

56.12%

META:

6.09%

Daily Std Dev

TXG:

66.67%

META:

30.33%

Max Drawdown

TXG:

-94.29%

META:

-76.74%

Current Drawdown

TXG:

-94.29%

META:

-5.68%

Fundamentals

Market Cap

TXG:

$1.48B

META:

$1.78T

EPS

TXG:

-$1.52

META:

$23.86

Total Revenue (TTM)

TXG:

$610.79M

META:

$164.50B

Gross Profit (TTM)

TXG:

$419.81M

META:

$134.34B

EBITDA (TTM)

TXG:

-$133.99M

META:

$81.63B

Returns By Period

In the year-to-date period, TXG achieves a -19.50% return, which is significantly lower than META's 18.67% return.


TXG

YTD

-19.50%

1M

-28.47%

6M

-48.04%

1Y

-75.20%

5Y*

-32.50%

10Y*

N/A

META

YTD

18.67%

1M

12.71%

6M

30.86%

1Y

48.87%

5Y*

27.21%

10Y*

24.42%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

TXG vs. META — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TXG
The Risk-Adjusted Performance Rank of TXG is 44
Overall Rank
The Sharpe Ratio Rank of TXG is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of TXG is 11
Sortino Ratio Rank
The Omega Ratio Rank of TXG is 22
Omega Ratio Rank
The Calmar Ratio Rank of TXG is 55
Calmar Ratio Rank
The Martin Ratio Rank of TXG is 99
Martin Ratio Rank

META
The Risk-Adjusted Performance Rank of META is 8686
Overall Rank
The Sharpe Ratio Rank of META is 8888
Sharpe Ratio Rank
The Sortino Ratio Rank of META is 8181
Sortino Ratio Rank
The Omega Ratio Rank of META is 8181
Omega Ratio Rank
The Calmar Ratio Rank of META is 9393
Calmar Ratio Rank
The Martin Ratio Rank of META is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TXG vs. META - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Meta Platforms, Inc. (META). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for TXG, currently valued at -1.14, compared to the broader market-2.000.002.00-1.141.56
The chart of Sortino ratio for TXG, currently valued at -2.27, compared to the broader market-4.00-2.000.002.004.006.00-2.272.06
The chart of Omega ratio for TXG, currently valued at 0.72, compared to the broader market0.501.001.502.000.721.28
The chart of Calmar ratio for TXG, currently valued at -0.81, compared to the broader market0.002.004.006.00-0.812.57
The chart of Martin ratio for TXG, currently valued at -1.36, compared to the broader market-10.000.0010.0020.0030.00-1.367.78
TXG
META

The current TXG Sharpe Ratio is -1.14, which is lower than the META Sharpe Ratio of 1.56. The chart below compares the historical Sharpe Ratios of TXG and META, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-1.14
1.56
TXG
META

Dividends

TXG vs. META - Dividend Comparison

TXG has not paid dividends to shareholders, while META's dividend yield for the trailing twelve months is around 0.22%.


TTM2024
TXG
10x Genomics, Inc.
0.00%0.00%
META
Meta Platforms, Inc.
0.22%0.34%

Drawdowns

TXG vs. META - Drawdown Comparison

The maximum TXG drawdown since its inception was -94.29%, which is greater than META's maximum drawdown of -76.74%. Use the drawdown chart below to compare losses from any high point for TXG and META. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-94.29%
-5.68%
TXG
META

Volatility

TXG vs. META - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 19.92% compared to Meta Platforms, Inc. (META) at 5.69%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than META based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%SeptemberOctoberNovemberDecember2025February
19.92%
5.69%
TXG
META

Financials

TXG vs. META - Financials Comparison

This section allows you to compare key financial metrics between 10x Genomics, Inc. and Meta Platforms, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab